Angelika Adamus-Grabicka

Dr. Angelika Adamus-Grabicka

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
JKJulia Kaźmierczak-Barańska
Julia Kaźmierczak-Barańska
KBKarolina Boguszewska
Karolina Boguszewska
AAAngelika Adamus-Grabicka
Angelika Adamus-Grabicka
Boleslaw T. KarwowskiBoleslaw T. Karwowski
Boleslaw T. Karwowski
Vitamin C has been known for decades. It is common in everyday use as an element of the diet, supplementation, and a preservative. For years, research has been conducted to precisely determine the mechanism of action of ascorbate in the cell. Available results indicate its multi-directional cellular effects. Vitamin C, which belongs to antioxidants scavenging free radicals, also has a ‘second face’—as a pro-oxidative factor. However, whether is the latter nature a defect harmful to the cell, or whether a virtue that is a source of benefit? In this review, we discuss the effects of vitamin C treatment in cancer prevention and the role of ascorbate in maintaining redox balance in the central nervous system (CNS). Finally, we discuss the effect of vitamin C supplementation on biomarkers of oxidative DNA damage and review the evidence that vitamin C has radioprotective properties.

Verified
Journal Article
Open access
PDF file
AAAngelika Adamus-Grabicka
Angelika Adamus-Grabicka
PHPaweł Hikisz
Paweł Hikisz
JSJoanna Sikora
Joanna Sikora
The incidence of skin cancer continues to grow. There are an estimated 1.5 million new cases each year, of which nearly 350,000 are melanoma, which is often fatal. Treatment is challenging and often ineffective, with conventional chemotherapy playing a limited role in this context. These disadvantages can be overcome by the use of nanoparticles and may allow for the early detection and monitoring of neoplastic changes and determining the effectiveness of treatment. This article briefly reviews the present understanding of the characteristics of skin cancers, their epidemiology, and risk factors. It also outlines the possibilities of using nanotechnology, especially nanoparticles, for the transport of medicinal substances. Research over the previous decade on carriers of active substances indicates that drugs can be delivered more accurately to the tumor site, resulting in higher therapeutic efficacy. The article describes the application of liposomes, carbon nanotubes, metal nanoparticles, and polymer nanoparticles in existing therapies. It discusses the challenges encountered in nanoparticle therapy and the possibilities of improving their performance. Undoubtedly, the use of nanoparticles is a promising method that can help in the fight against skin cancer.

1 April 2020 in Molecules
Verified
Journal Article
Open access
PDF file
AAAngelika Adamus-Grabicka
Angelika Adamus-Grabicka
Magdalena Markowicz-PiaseckaMagdalena Markowicz-Piasecka
Magdalena Markowicz-Piasecka
MCMarcin Cieslak
Marcin Cieslak
KKKarolina Królewska-Golińska
Karolina Królewska-Golińska
PHPaweł Hikisz
Paweł Hikisz
EBElzbieta Budzisz
Elzbieta Budzisz
A series of 3-benzylidenechrmanones 1, 3, 5, 7, 9 and their spiropyrazoline analogues 2, 4, 6, 8, 10 were synthesized. X-ray analysis confirms that compounds 2 and 8 crystallize in a monoclinic system in P21/n space groups with one and three molecules in each asymmetric unit. The crystal lattice of the analyzed compounds is enhanced by hydrogen bonds. The primary aim of the study was to evaluate the anti-proliferative potential of 3-benzylidenechromanones and their spiropyrazoline analogues towards four cancer cell lines. Our results indicate that parent compounds 1 and 9 with a phenyl ring at C2 have lower cytotoxic activity against cancer cell lines than their spiropyrazolines analogues. Analysis of IC50 values showed that the compounds 3 and 7 exhibited higher cytotoxic activity against cancer cells, being more active than the reference compound (4-chromanone or quercetin). The results of this study indicate that the incorporation of a pyrazoline ring into the 3-arylideneflavanone results in an improvement of the compounds’ activity and therefore it may be of use in the search of new anticancer agents. Further analysis allowed us to demonstrate the compounds to have a strong inhibitory effect on the cell cycle. For instance, compounds 2, 10 induced 60% of HL-60 cells to be arrested in G2/M phase. Using a DNA-cleavage protection assay we also demonstrated that tested compounds interact with DNA. All compounds at the concentrations corresponding to cytotoxic properties are not toxic towards red blood cells, and do not contribute to hemolysis of RBCs.

1 December 2018 in Molecules
Verified
Journal Article
Open access
PDF file
AAAngelika Adamus-Grabicka
Angelika Adamus-Grabicka
Magdalena Markowicz-PiaseckaMagdalena Markowicz-Piasecka
Magdalena Markowicz-Piasecka
Michał Błażej PonczekMichał Błażej Ponczek
Michał Błażej Ponczek
JKJoachim Kusz
Joachim Kusz
Magdalena MałeckaMagdalena Małecka
Magdalena Małecka
EBElzbieta Budzisz
Elzbieta Budzisz
The aim of this study was to determine the cytotoxic effect of 3-arylidenechromanone (1) and 3-arylideneflavanone (2) on HL-60 and NALM-6 cell lines (two human leukemia cell lines) and a WM-115 melanoma cell line. Both compounds exhibited high cytotoxic activity with higher cytotoxicity exerted by compound 2, for which IC50 values below 10 µM were found for each cell line. For compound 1, the IC50 values were higher than 10 µM for HL-60 and WM-115 cell lines, but IC50 < 10 µM was found for the NALM-6 cell line. Both compounds, at the concentrations close to IC50 (concentration range: 5–24 µM/L for compound 1 and 6–10 µM/L for compound 2), are not toxic towards red blood cells. The synthesized compounds were characterized using spectroscopic methods 1H- and 13C-NMR, IR, MS, elemental analysis, and X-ray diffraction. The lipophilicity of both synthesized compounds was determined using an RP-TLC method and the logP values found were compared with the theoretical ones taken from the Molinspiration Cheminformatics (miLogP) software package. The mode of binding of both compounds to human serum albumin was assessed using molecular docking methods.

6 July 2020 in Acta Crystallographica Section C Structural Chemistry
Verified
Journal Article
Closed access
PDF file
Magdalena MałeckaMagdalena Małecka
Magdalena Małecka
JKJoachim Kusz
Joachim Kusz
LELars Eriksson
Lars Eriksson
AAAngelika Adamus-Grabicka
Angelika Adamus-Grabicka
EBElzbieta Budzisz
Elzbieta Budzisz

Verified
Journal Article
Open access
PDF file
AAAngelika Adamus-Grabicka
Angelika Adamus-Grabicka
MDMateusz Daśko
Mateusz Daśko
PHPaweł Hikisz
Paweł Hikisz
JKJoachim Kusz
Joachim Kusz
Magdalena MałeckaMagdalena Małecka
Magdalena Małecka
EBElzbieta Budzisz
Elzbieta Budzisz
In this study, we evaluated the antiproliferative potential, DNA damage, crystal structures, and docking calculation of two spiropyrazoline derivatives. The main focus of the research was to evaluate the antiproliferative potential of synthesized compounds towards eight cancer cell lines. Compound I demonstrated promising antiproliferative properties, especially toward the HL60 cell line, for which IC50 was equal to 9.4 µM/L. The analysis of DNA damage by the comet assay showed that compound II caused DNA damage to tumor lineage cells to a greater extent than compound I. The level of damage to tumor cells of the HEC-1-A lineage was 23%. The determination of apoptotic and necrotic cell fractions by fluorescence microscopy indicated that cells treated with spiropyrazoline-based analogues were entering the early phase of programmed cell death. Compounds I and II depolarized the mitochondrial membranes of cancer cells. Furthermore, we performed simple docking calculations, which indicated that the obtained compounds are able to bind to the PARP1 active site, at least theoretically (the free energy of binding values for compound I and II were −9.7 and 8.7 kcal mol−1, respectively). In silico studies of the influence of the studied compounds on PARP1 were confirmed in vitro with the use of eight cancer cell lines. The degradation of the PARP1 enzyme was observed, with compound I characterized by a higher protein degradation activity.